Vismodegib is the first selective hedgehog pathway inhibitor approved to treat locally advanced and metastatic basal cell carcinoma (BCC). Limited information is available concerning its role in managing advanced BCC around the eye.
Methods
The medical literature was searched for cases of nonsyndromic periocular BCC treated with vismodegib. Clinical information was abstracted and analyzed. In addition, a review of the pharmacology of vismodegib, including general effectiveness and safety, was conducted.
Results
Thirty study patients with nonsyndromic periocular BCC treated with vismodegib were found in the literature. Vismodegib was used in 3 ways: medical therapy, adjuvant therapy prior to surgery or radiotherapy, and treatment of positive surgical margins. Complete regression was reported in 9 study patients (30%), with follow-up visits after therapy averaging fewer than 5 months. Four study participants developed squamous cell carcinoma while receiving treatment.
Conclusions
Too few cases exist to draw any conclusions on the role that vismodegib might play in the management of periocular BCC. In addition, long-term follow-up data are not yet available. Although the objective response rate of advanced BCC is impressive in study patients receiving vismodegib, well-controlled clinical studies are needed to determine whether vismodegib has any impact on survival or quality of life.
References
1.
MargoC.E., WaltzK.Basal cell carcinoma of the eyelid and periocular skin.Surv Ophthalmol.1993; 38(2): 169–192.
2.
AxelsonM., LiuK., JiangX.U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.Clin Cancer Res.2013; 19(9): 2289–2293.
3.
SofenH., GrossK.G., GoldbergL.H.A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.J Am Acad Dermatol.2015; 73(1): 99–105.e1.
ErdemG.U., SendurM.A., OzdemirN.Y.A comprehensive review of the role of Hedgehog pathway and vismodegib in the management of basal cell carcinoma.Curr Med Res Opin.2015; 31(4): 743–756.
6.
SekulicA., MigdenM.R., OroA.E.Efficacy and safety of vismodegib in advanced basal cell carcinoma.N Engl J Med.2012; 366(23): 2171–2179.
7.
GillH.S., MoscatoE.E., ChangA.L.Vismodegib for periocular and orbital basal cell carcinoma.JAMA Ophthalmol.2013; 131(12): 1591–1594.
8.
DemirciH., WordenF., NelsonC.C.Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area.Ophthal Plast Reconstr Surg.2015; 31(6): 463–466.
9.
AllyM.S., AasiS., WysongA.An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high risk basal cell carcinoma.J Am Acad Dermatol.2014; 71(5): 904–911.e1.
10.
PollomE.L., BuiT.T., ChangA.L.S.Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma.JAMA Dermatol.2015; 151(9): 998–1001.
11.
AasiS., SilkissR., TangJ.Y.New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.JAMA Dermatol.2013; 149(2): 242–243.
12.
PapastefanousV.P., RenéC.. Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion.Ophthal Plast Reconstr Surg.2015. Epub ahead of print.
GeeraertP., WilliamsJ.S., BrownellI.Targeting the hedgehog pathway to treat basal cell carcinoma.J Drugs Dermatol.2013; 12(5): 519–523.
17.
ChangA.L., SolomonJ.A., Hainswor thJ.D.Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.J Am Acad Dermatol.2014; 70(1): 60–69.
18.
RidkyT.W., CotsarelisG.Vismodegib resistance in basal cell carcinoma: not a smooth fit.Cancer Cells.2015; 27(3): 315–316.
19.
RobargeK.D., BruntonS.A., CastanedoG.M.GDC-0449: a potent inhibitor of the hedgehog pathway.Bioorg Med Chem Lett.2009; 19(19): 5576–5581.
20.
ProctorA.E., ThompsonL.A., O'BryantC.L.Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma.Ann Pharmcother.2014; 48(1): 99–106.
21.
GrahamR.A., LumB.L., MorrisonG.A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.Drug Metab Dispos.2011; 39(8): 1460–1467.
22.
GrahamR.A., HopC.E., BorinM.T.Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.Br J Clin Pharmacol.2012; 74(5): 788–796.
23.
Vismodegib [package insert].South San Francisco, CA: Genentech; 2012.
24.
Von HoffD.D., LoRussoP.M., RudinC.M.Inhibition of hedgehog pathway in advanced basal cell carcinoma.N Engl J Med.2009; 361(12): 1164–1172.
25.
LoRussoP.M., RudinC.M., ReddyJ.C.Phase 1 trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.Clin Cancer Res.2011; 17(8): 2502–2511.
26.
TangJ.Y., Mackay-WiggansJ.M., AszterbaumM.Inhibiting the hedgehog pathway in patients with basal cell nevus syndrome.N Engl J Med.2012; 366(23): 2180–2188.
27.
SekulicA., MigdenM.R., LewisK.ERIVANCE BCC Investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.J Am Acad Dermatol.2015; 72(6): 1021–1026.
28.
Basset-SequinN., HauschildA., GrobJ.J.Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.Lancet Oncol.2015; 16(6): 729–736.
29.
KahanaA., WordenF.P., ElnerV.M.Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.JAMA Ophthalmol.2013; 131(10): 1364–1366.
30.
PerisK., LicitraL., AsciertoP.A.Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.Future Oncology.2015; 11(4): 703–712.
PoulalhonN., DalleS., BalmeB., ThomasL.Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib.Dermatology.2015; 230(2): 101–104.
33.
SaintesC., Saint-JeanM., BrocardA.Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib.J Eur Acad Dermatol Venereol.2015; 29(5): 1006–1009.
34.
AtwoodS.X., LiM., LeeA.GLI activation by atypical protein kinase C i/? regulates the growth of basal cell carcinomas.Nature.2013; 28: 494 (7438): 484-488.
35.
SharpeH.J., PauG., DijkgraafG.J.Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.Cancer Cell.2015; 9(3): 27: 327–341.
36.
ZhaoJ., QuanH., ZieC., LouL.NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.Pharmacol Res Perspect.2014; 2(3): e00043.
37.
AshM.M., JollyP.S.Cholestatic hepatic injury associated with vismodegib, aspirin, naproxen use: a case study and review of vismodegib safety.Int J Dermatol.2015; 54(3): 370–374.
38.
VentarolaD.J., SilversteinD.I.Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance.J Am Acad Dermatol.2014; 71(2): 397–398.
39.
ZhangY., BaickerK., NewhouseJ.P.. Geographic variation in Medicare drug spending.N Engl J Med.2010; 363(5): 405–409.
40.
AcostaA., CiapponiA., AaserudM.Pharmaceutical policies: effects of reference pricing, other pricing and purchasing policies.Cochrane Database Syst Rev.2014; 10: CD005959.
LuxenbergM.N., GuthrieT.H.Jr. Chemotherapies of eyelid and peri-orbital tumors.Trans Am Ophthalmol Soc.1985; 83: 162–180.
43.
LuxenbergM.N., GutherieT.H.Jr. Chemotherapy of basal cell and squamous cell carcinoma of the eyelids and periorbital tissues.Ophthalmology.1986; 93(4): 504–510.
44.
SmithC.M., ReynardA.M., eds. Textbook of Pharmacology.Philadelphia, PA: WB Saunders; 1992.
45.
[No authors listed]. Vismodegib (ERIVEDGE) in basal cell carcinoma: too many unknowns.Prescrire Int.2015; 24(156): 11–14.
